Get the Stockscreener App
15.04
0.66%
-0.105
Janux Therapeutics Inc stock is traded at $15.04, with a volume of 582.31K.
It is down -0.66% in the last 24 hours and up +6.51% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$15.14
Open:
$14.92
24h Volume:
582.31K
Relative Volume:
0.30
Market Cap:
$904.32M
Revenue:
$439.00K
Net Income/Loss:
$-105.64M
P/E Ratio:
-8.3528
EPS:
-1.8
Net Cash Flow:
$-60.70M
1W Performance:
+9.30%
1M Performance:
+6.51%
6M Performance:
-43.16%
1Y Performance:
-66.27%
1-Day Range:
$14.88
$15.49
1-Week Range:
$12.80
$15.49
52-Week Range:
$12.80
$47.58
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
15.04 | 910.64M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
JANX Enters Global Oncology Collaboration With BMY, Stock Rises - Finviz
Janux Therapeutics Inks Global Oncology Collaboration With BMS - TipRanks
Janux Therapeutics Signs Exclusive License and Collaboration Agreement With Bristol-Myers Squibb - TradingView — Track All Markets
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeHere's Why - MarketBeat
Janux Therapeutics Pairs With BMS on Novel Tumor-Activated Therapeutic - Contract Pharma
Key facts: Bristol Myers Squibb signs $850M deal with Janux; partners with Microsoft for AI - TradingView — Track All Markets
BMS Tries Again With T Cell Engagers, Turning to Janux to Develop New Tumor-Activated Therapy - MedCity News
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
BMS bets on Janux’s novel solid tumour therapy through $850m deal - Yahoo Finance
Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors - marketscreener.com
Bristol Myers buys into Janux’s ‘masked’ T cell engagers - BioPharma Dive
Janux, Bristol Myers Squibb partner on tumor-activated therapy By Investing.com - Investing.com Canada
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters
Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb - Stocktwits
Janux stock rises after Bristol Myers Squibb collaboration deal By Investing.com - Investing.com UK
Janux stock rises after Bristol Myers Squibb collaboration deal - Investing.com
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments - BioSpace
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million - Intellectia AI
Bristol Myers (BMY) Partners with Janux Therapeutics on Cancer T - GuruFocus
Janux Shares Rise On Solid Tumor License Agreement with Bristol Myers Squibb - marketscreener.com
Bristol Myers inks licensing deal with Janux for cancer therapy - Seeking Alpha
Janux Therapeutics stock soars after Bristol Myers Squibb collaboration By Investing.com - Investing.com Canada
Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy - TradingView — Track All Markets
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors - Business Wire
Clear Str Downgrades Janux Therapeutics (NASDAQ:JANX) to Hold - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Reaches New 1-Year LowWhat's Next? - MarketBeat
Clear Street downgrades Janux Therapeutics stock to Hold on efficacy concerns - Investing.com Canada
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat
JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target - MSN
Energy Moves: Is Janux Therapeutics Inc part of any ETFQuarterly Market Review & Expert Approved Momentum Ideas - baoquankhu1.vn
Volume Report: What is Janux Therapeutics Inc. s debt to equity ratioJuly 2025 Price Swings & Risk Controlled Daily Plans - baoquankhu1.vn
Moving Averages: How Janux Therapeutics Inc stock reacts to oil pricesWatch List & Advanced Swing Trade Entry Alerts - Bộ Nội Vụ
Risk Report: Can Janux Therapeutics Inc stock reach 100 price targetJuly 2025 Update & Daily Growth Stock Tips - Bộ Nội Vụ
Treasury Yields: Can Janux Therapeutics Inc stock reach 100 price targetWeekly Risk Report & Real-Time Market Sentiment Reports - Bộ Nội Vụ
(JANX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Pullback Watch: Will Janux Therapeutics Inc stock maintain dividend yieldJuly 2025 Weekly Recap & Daily Entry Point Trade Alerts - Bộ Nội Vụ
Will Janux Therapeutics Inc. stock maintain dividend yield2025 Stock Rankings & Capital Efficiency Focused Ideas - Улправда
Aug Retail: Will Janux Therapeutics Inc. stock benefit from upcoming earnings reportsWeekly Trend Summary & Fast Exit Strategy with Risk Control - Улправда
Can Janux Therapeutics Inc. stock deliver sustainable ROEAnalyst Upgrade & Safe Swing Trade Setup Alerts - Улправда
Will Janux Therapeutics Inc. stock benefit from infrastructure spendingMarket Activity Recap & Weekly Setup with ROI Potential - Улправда
Why Janux Therapeutics Inc. stock remains resilientAutomated Trading Signals & Capital Planning and Optimization - Улправда
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BofA Adjusts Price Target on Janux Therapeutics to $35 From $49, Maintains Buy Rating - marketscreener.com
Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month LowWhat's Next? - MarketBeat
Janux Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Pre-market Movers: RSLS, STSS, VERO, KTTA... - RTTNews
Janux Therapeutics’ CMO McIver sells $37k in shares By Investing.com - Investing.com India
Andrew Hollman Meyer Sells 1,879 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics CEO Campbell sells $110k in stock By Investing.com - Investing.com Canada
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):